-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：巴克萊銀行公佈了2026年第一季穩健的業績，稅前利潤為28.1億英鎊（同比增長3%），股本回報率（RoTE）為13.5%，與市場普遍預期的28.3億英鎊基本一致。總收入成長6%至81.6億英鎊，反映出各業務部門的全面成長。其中，投資銀行創下季度營收新高，超過40億英鎊（全球市場業務成長6%，銀行手續費收入成長17%），英國業務也持續成長，淨利息收入（NII）成長12%。鑑於2026年第一季展現出的強勁勢頭，我們認為巴克萊銀行仍有望實現其目標。所有業務部門均實現了兩位數的收益，包括美國消費者銀行的股本回報率從4.5%提升至18.8%。管理層重申了2026年和2028年的所有財務目標，並表示有信心在多元化平台的支持下，分別在2026年和2028年實現超過12%和超過14%的股本回報率（RoTE）。公司資本實力依然強勁，一級資本充足率（CET1）達到14.1%，接近13%-14%的目標區間上限，這為在完成正在進行的10億英鎊股票回購計畫後宣布的5億英鎊股票回購計畫提供了支持。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan